Trial Profile

A phase 1/2 study of 4D-110 for Choroideremia

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 4D-110 (Primary)
Indications Choroideraemia
Focus Adverse reactions; Therapeutic Use

Most Recent Events

16 Jan 2023 New trial record
09 Jan 2023 According to a 4D Molecular Therapeutics media release, enrollment in this phase 1/2 study has been completed in the fourth quarter of 2022. The company will continue to follow these patients for 24 months and anticipate clinical data updates in 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com